[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AZ Sint-Jan AV\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":265},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,70,93,119,147,169,194,220,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100403168","added-value-of-vein-of-marshal-ethanol-infusion-compared-to-superior-vena-cava-isolation-alone-in-patients-undergoing-repeat-ablation-for-recurrent-paroxysmal-atrial-fibrillation-despite-durable-pv-isolation-100403168",false,"NCT04529785","Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation","Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable Pulmonary Vein Isolation","VEIN-AF","Inclusion Criteria:\n\n* Patients older than 18 years\n* Patients scheduled for a repeat ablation of PAF after a previous PVI\n* Confirmation of lasting pulmonary vein isolation at the time of randomization\n\nExclusion Criteria:\n\n* Patients with persistent atrial fibrillation\n* Previous ablation with isolation of the SVC, roofline, mitral line or previous vein of Marshal ethanol infusion\n* Left atrial thrombus. Left atrial appendage thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.\n* Left ventricular ejection fraction \\\u003C35%.\n* Cardiac surgery within the previous 90 days.\n* Expecting cardiac transplantation or other cardiac surgery within 180 days.\n* Coronary percutaneous transluminal coronary angioplasty\u002Fstenting within the previous 90 days or myocardial infarction within the previous 60 days.\n* Documented history of a thromboembolic event within the previous 90 days.\n* Diagnosed atrial myxoma.\n* Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment\n* Women who are pregnant or who plan to become pregnant during the study.\n* Acute illness or active infection at time of index procedure\n* Advanced renal insufficiency\n* Unstable angina.\n* History of blood clotting or bleeding abnormalities.\n* Contraindication to anticoagulation.\n* Life expectancy less than 1 year.\n* Presence of a condition that precludes vascular access.\n* International Normalized Ratio greater than 3.5 within 24 hours of procedure - for patients taking warfarin.\n* Patient cannot be removed from antiarrhythmic drugs for reasons other than AF.\n* Unwilling or unable to provide informed consent.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The superior vena cava (SVC) is one of the most common non pulmonary vein (PV)-triggers for atrial tachyarrhythmias. SVC electrical isolation can be reached by circular radiofrequency (RF)-ablation under close monitoring of the phrenic nerve. However, adding substrate modification and vein of Marshal (VoM) ethanol infusion to the ablation procedure might substantially improve long-term outcomes.\n\nThe aim of this study is to evaluate the recurrence rate 1 year after the index ablation in patients undergoing a redo ablation for recurrent paroxysmal atrial fibrillation (PAF) despite durable pulmonary vein isolation (PVI) with either SVC isolation alone or with substrate modification including vein of Marshal ethanolisation in addition to SVC isolation alone",[27],"Paroxysmal Atrial Fibrillation","RECRUITING","2026-05-07",{"date":31,"type":32},"2026-05-12","ACTUAL",{"date":34,"type":32},"2020-09-11",{"date":36,"type":21},"2027-12-31",{"name":38,"class":39},"AZ Sint-Jan AV","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100631499","arrhythmic-risk-in-myocarditis-outcome-research-100631499","NCT07501481","Arrhythmic Risk in Myocarditis Outcome Research","Incidence, Clinical Impact, and Prediction of Ventricular Arrhythmia in Patients With Acute Myocarditis","ARMOR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Hospitalization for acute myocarditis\n* Confirmation of the diagnosis of AM by at least one of the following: (1) Cardiac magnetic resonance according to the revised 2018 Lake Louise Criteria; (2) Endomyocardial biopsy according to the Dallas criteria with associated immunohistochemical and molecular criteria; (3) Cardiac computed tomography with compatible late iodine enhancement\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Concomitant acute coronary syndrome",{"count":50,"type":21},1500,"OBSERVATIONAL","The goal of this observational, retrospective, multicenter study is to characterize the arrhythmic burden and identify predictive factors for ventricular arrhythmias (VAs) in adult patients hospitalized for acute myocarditis (AM). The main questions it aims to answer are:\n\n* What is the incidence of sustained ventricular arrhythmias during the index hospitalization in patients with acute myocarditis?\n* What clinical, biological, electrocardiographic, and imaging factors predict the occurrence of sustained ventricular arrhythmias during hospitalization and after discharge?\n\nResearchers will compare patients who developed sustained VAs during hospitalization to those who did not, in order to identify independent predictors of arrhythmic events and develop a validated risk stratification score.\n\nParticipants' medical records from 2020 to 2024 will be reviewed to collect:\n\n* Baseline demographic, clinical, biological, electrocardiographic, and imaging data at admission\n* In-hospital management strategies and outcomes, including mortality, cardiogenic shock, and heart replacement therapy\n* Long-term follow-up data including VA recurrence, sudden cardiac death, and development of cardiomyopathy, with censoring applied on January 1, 2026",[54,55],"Myocarditis Acute","Ventricular Arrhythmia",[57,58,59,60],"acute myocarditis","ventricular arrhythmia","ventricular tachycardia","ventricular fibrillation","NOT_YET_RECRUITING","2026-03-26",{"date":64,"type":32},"2026-03-30",{"date":66,"type":21},"2026-03-01",{"date":68,"type":21},"2027-03-31",{"name":38,"class":39},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":78,"studyType":51,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100605002","observational-belgian-registry-of-implanted-ev-icd-to-evaluate-parameters-and-complications-of-the-new-device-in-real-world-settings-100605002","NCT07156851","Observational BELgian Registry of Implanted EV-ICD to Evaluate Parameters and Complications of the New Device in Real World Settings","BELIEVE","Inclusion Criteria:\n\n* At least 18 years old\n* Previous or planned EV-ICD implantation (successful or not)\n* Informed consent signed\n\nExclusion Criteria:\n\n* Patients who did not undergo any step of the implantation procedure",{"count":20,"type":21},"15 Years","The goal of this observational study is to follow all patients implanted with extravascular implantable cardioverter-defibrillators (EV-ICDs) in Belgium throughout the lifetime of the devices. The main goal of the study is to keep track of:\n\n* all parameters of the device\n* complications\n* arrhythmia detection and therapy delivery\n* clinical endpoints (quality of life, cardiac and infectious events) Participants who underwent or will undergo an EV-ICD implantation as part of their regular medical care will be asked if data can be collected from their medical record. No additional tasks are required for the study.",[81],"Implantable Cardioverter Defibrillator (ICD)",[83,84],"Extravascular implantable cardioverter-defibrillator","EV-ICD","2025-08-27",{"date":87,"type":32},"2025-09-05",{"date":89,"type":21},"2025-11",{"date":91,"type":21},"2040-07-01",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100590035","posterior-mitral-isthmus-line-with-vein-of-marshall-ethanolisation-compared-with-anterior-mitral-lines-in-patients-with-persistent-atrial-fibrillation-100590035","NCT06962176","Posterior Mitral Isthmus Line With Vein of Marshall Ethanolisation Compared With Anterior Mitral Lines in Patients With Persistent Atrial Fibrillation","MIVANT","Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years, diagnosed with symptomatic persistent AF with clinical indication for left atrial ablation with a mitral isthmus line. Pulmonary vein will be isolated in all patients before starting the mitral isthmus line (during a previous or the same procedure)\n\nExclusion Criteria:\n\n* Previous mitral line or any other left atrial ablation beyond pulmonary vein isolation\n* Left atrial (LA) thrombus. LA thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.\n* LA diameter greater than 60 mm on long axis parasternal view, or left atrial volume more than 250 cc.\n* Left ventricular ejection fraction \\\u003C25%.\n* Cardiac surgery within the previous 90 days.\n* Expecting cardiac transplantation or other cardiac surgery within 180 days.\n* Percutaneous transluminal coronary angioplasty\u002Fstenting or myocardial infarction within the previous 30 days.\n* Documented history of a thromboembolic event within the previous 60 days.\n* Diagnosed atrial myxoma.\n* Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment\n* Women who are pregnant or who plan to become pregnant during the study.\n* Acute illness or active infection at time of index procedure\n* Renal insufficiency\n* Unstable angina.\n* History of blood clotting or bleeding abnormalities.\n* Contraindication to anticoagulation.\n* Life expectancy less than 1 year.\n* Uncontrolled heart failure.\n* Presence of a condition that precludes vascular access.\n* International normalised ratio (INR) greater than 4 within 24 hours of procedure - for patients taking warfarin.\n* Unwilling or unable to provide informed consent.","80 Years",{"count":102,"type":21},146,[24],"The goal of this clinical study is to find out which treatment works best for people with persistent atrial fibrillation (a type of irregular heartbeat). Researchers are comparing two types of heart ablation procedures:\n\n* An anterior mitral line ablation (a treatment at the front part of the heart)\n* A posterior mitral line ablation (at the back of the heart), sometimes with an extra step using a small vein called the Vein of Marshall\n\nThe main questions the study aims to answer are:\n\n* Which approach works better at fixing the heart rhythm?\n* Which approach is safer (less complications)?\n\nPeople who take part in this study will:\n\n* Undergo an ablation procedure as part of their standard care\n* Attend follow-up visits at 1, 3, and 6 months\n* Have tests like ECGs, heart ultrasound (echocardiogram), blood tests, heart rhythm monitors (Holter), and a heart CT scan",[106],"Persistent Atrial Fibrillation",[106,108,109,110],"Catheter ablation","Vein of Marshall ethanolization","Mitral line ablation","2025-04-29",{"date":113,"type":32},"2025-05-08",{"date":115,"type":21},"2025-07",{"date":117,"type":21},"2027-07",{"name":38,"class":39},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100523444","phase-3-colchicine-in-belgium-in-patients-with-coronary-artery-disease-after-percutaneous-coronary-intervention-100523444","NCT06095765","Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention","Colchicine in Belgium in Patients With Coronary Artery Disease","COL BE PCI","Inclusion Criteria:\n\n1. Age ≥45 years.\n2. Coronary artery disease treated with PCI and optimal medical therapy, with at least one additional risk factor (based on SMART):\n\n   1. Age ≥ year\n   2. Diabetes mellitus, on treatment or new diagnosis with HbA1c ≥6.5%\n   3. Current smoking\n   4. Treated hypertension or lood pressure systolic ≥ 4 mmHg or diastolic ≥ mmHg\n   5. Total cholesterol \\>240 mg\u002Fdl untreated, or treated LDL \\>70 mg\u002Fdl\n   6. HDL \\\u003C40 mg\u002Fdl\n   7. hsCRP \\>2 mg\u002FL AND chronic coronary syndrome (CCS)\n   8. eGFR \\\u003C60 ml\u002Fmin (MDRD)\n   9. history of vascular disease:\n\n      * CAD (PCI prior to index, CABG, MI)\n      * stroke (ischemic or hemorrhagic)\n      * carotid artery revascularisation\n      * PAD (revascularisation, ABI \\\u003C0.85 at rest, amputation due to atherosclerotic disease)\n      * AAA (repair, distal aortic anteroposterior diameter \\>3.0cm)\n3. Able to be enrolled\u002Frandomized between 2 hour and 5 days post PCI.\n4. Written informed consent.\n\nExclusion Criteria:\n\n1. Women who are pregnant, breastfeeding, or of childbearing potential who are not using an effective method of contraception. Or women who intend to donate oocytes.\n2. Men who plan to father children during the study period or who are unwilling to use effective forms of contraception. Or men who intend to donate sperm.\n3. Any contraindication or known intolerance to colchicine.\n4. Chronic use of -or need for- colchicine.\n5. Auto-immune disease or other condition requiring current or planned chronic systemic steroids, immunosuppressant or biologic drug targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab etc.).\n6. Creatinine clearance \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n7. Cirrhosis Child-Pugh stadium B and C, or acute severe liver disease\n8. Neuromuscular disease or non-transient CK levels \\> 5 x ULN (unless due to MI).\n9. History of cancer or lymphoproliferative disease within the last 3 years, other than successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma, or localized cervix carcinoma in situ.\n10. Current or planned use of any strong inhibitor of CYP3A4 or p-glycoprotein: macrolide antibiotics (clarithromycin, telithromycin), azole antifungal agents (ketoconazole, voriconazole, fluconazole, itraconazole), cyclosporine, HIV medication (ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir).\n11. Chronic diarrhea, or inflammatory owel disease (Crohn's disease or ulcerative colitis).\n12. Drug or alcohol abuse.\n13. Planned cardiovascular intervention known on the day of screening.\n14. Currently enrolled in another investigational trial.\n15. Considered to be an unsuitable candidate by the investigator.","45 Years",{"count":129,"type":21},2770,[131],"PHASE3","The main aim of this trial is to determine whether there are fewer cardiovascular events when patients with coronary artery disease take a low dose of colchicine of 0.5 mg daily on top of optimal standard treatment after treatment with PCI, compared with placebo in combination with optimal standard treatment. More specifically, we aim to investigate the benefits of a daily low dose of colchicine in patients with coronary artery disease after treatment with PCI, to confirm that a daily low dose of colchicine helps prevent additional incidents in coronary artery disease, and to identify a subgroup of patients with CAD who are at increased risk for cardiovascular events and could benefit most from colchicine.",[134],"Coronary Artery Disease",[136,137],"percutaneous coronary intervention","colchicine","2024-03-07",{"date":140,"type":32},"2024-03-08",{"date":142,"type":32},"2024-01-29",{"date":144,"type":21},"2028-03-01",{"name":38,"class":39},19,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":157,"studyType":51,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100483595","tribel-registry-national-belgian-registry-of-percutaneous-tricuspid-valve-repair-using-a-transcatheter-edge-to-edge-repair-technique-100483595","NCT05577078","TriBEL Registry: National Belgian Registry of Percutaneous Tricuspid Valve Repair Using a Transcatheter Edge-to-edge Repair Technique","TriBEL","Inclusion Criteria:\n\n* At least 18 years old\n* Eligible for TEER procedure\n* Informed consent signed\n\nExclusion Criteria:\n\n* Unwilling to provide informed consent","110 Years",{"count":156,"type":21},120,"5 Years","In this study, patients who have undergone or will undergo a transcatheter edge-to-edge repair (TEER) for tricuspid valve regurgitation (TR) will be followed up for 5 years. The goal of this prospective and retrospective, observational, non-randomized, multicenter registry is to confirm that TEER is a feasible, safe and effective treatment option for TR and to evaluate the long-term efficacy and safety of TEER.\n\nThe main endpoints are:\n\n* Change in tricuspid regurgitation grade: number of patients with a reduction in tricuspid regurgitation score by at least one grade\n* Composite of major adverse event: number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia)",[160],"Tricuspid Valve Regurgitation","2022-10-10",{"date":163,"type":32},"2022-10-13",{"date":165,"type":21},"2023-01-01",{"date":167,"type":21},"2029-12-31",{"name":38,"class":39},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100363097","validation-of-the-o-bridge-protocol-a-prospective-multicenter-trial-100363097","NCT04007783","Validation of the O-bridge Protocol: a Prospective, Multicenter Trial","Validation of the O-bridge Protocol, Ensuring Immediate or Delayed Prosthetic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction: a Prospective, Multicenter Trial","Inclusion Criteria:\n\n* Patients with a histologically or clinically confirmed diagnosis of ORN, MRONJ, as classified by respectively Lyons et al. (Lyons, et al., 2014) and Ruggiero et al. (Ruggiero, et al., 2009) (Ruggiero, et al., 2014) or a benign or malignant tumour located in the oral cavity and jaw bone (NCCN, 2015) (Sobin, et al., 2009), requiring marginal, segmental or total jaw resection\n* Patients eligible for jaw and oral cavity reconstruction combined with immediate\u002Fdelayed implant loading for fixed prosthetic rehabilitation\n* Patients not eligible for conventional removable prosthetic rehabilitation\n\nExclusion Criteria:\n\n* Patients not eligible to the abovementioned criteria\n* Patients with a clinically confirmed diagnosis of osteonecrosis not related to an oncological diagnosis or treatment\n* Patients with medical contraindications for jaw reconstruction combined with immediate implant loading for fixed prosthetic rehabilitation\n* Patients whose maternal language is non-Dutch or non-English will be excluded from the acoustic speech evaluation. A perceptual evaluation of speech intelligibility can still be performed.",{"count":177,"type":21},80,"Surgical reconstruction to restore oral function and aesthetics after major ablative surgery in the oral cavity forms a challenge to maxillofacial surgeons, and greatly impacts patient' quality of life (QOL). The \"Oncological-bridge (O-bridge®)\" protocol, which offers (immediate\u002Fdelayed) fixed prosthetic rehabilitation in a minimum of sessions and a strongly reduced two-week treatment time.",[180,181,182,183,184],"Benign or Malignant Tumour of the Oral Cavity","Stage III-IV Osteonecrosis","Mandibular Reconstruction","Fixed Dental Restoration","Quality of Life","2022-02-23",{"date":187,"type":32},"2022-02-24",{"date":189,"type":32},"2017-03-04",{"date":191,"type":21},"2027-12",{"name":38,"class":39},5,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":51,"phases":4,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":40},"100267540","3d-volumetric-changes-in-the-upper-airway-after-mma-in-osas-patients-and-the-implication-on-qol-a-prospective-registry-100267540","NCT02762175","3D Volumetric Changes in the Upper Airway After MMA in OSAS Patients and the Implication on QOL: A Prospective Registry","3D Volumetric Changes in the Upper Airway After Maxillomandibular Advancement in Obstructive Sleep Apnea Syndrome Patients and the Implication on Quality of Life: A Prospective Registry","MMA-OSAS","Inclusion Criteria:\n\n* Patients of all ages\n* Patients of all genders\n* Patients diagnosed with OSAS, based on an AHI ≥ 5\n* All consecutive OSAS patients operated by N. Neyt from January 2015 onwards\n\nExclusion Criteria:\n\n* Patients not eligible according to abovementioned criteria\n* Patients with morbid obesity (BMI \\>35), if judged non-eligible by the treating surgeon",{"count":203,"type":21},150,"6 Months","Background\n\nObstructive sleep apnea syndrome (OSAS) is a sleep-related breathing disorder characterized by intense snoring and repetitive complete or partial obstructions of the upper airway during sleep together with daytime sleepiness. Several non-invasive therapeutical options exist, however, they do not offer a permanent improvement. Maxillomandibular advancement (MMA) surgery is a procedure which changes the upper airway in a permanent way.\n\nObjectives\n\nThe investigators aim to develop a prospective database registering 3D volumetric changes of the upper airway and its anatomic subregions, the apnea-hypopnea index (AHI) and quality of life (QOL) of all consecutive patients eligible for MMA, performed by Dr. Neyt. Patient demographics, detailed virtual cone-beam computed tomography (CBCT) planning parameters, orthognathic surgery, polysomnographic and QOL data are being collected during consecutive visits within the framework of routine practice.\n\nDesign\n\nA prospective, observational cohort study\n\nStudy center\n\nGeneral Hospital (AZ) Sint-Jan Brugge-Oostende\n\nPopulation\n\nThe investigators would like to include all OSAS patients (AHI ≥ 5) requiring a MMA by Dr. Neyt starting from January 2015.\n\nEndpoints\n\nThe investigators aim to collect data that could provide information about the advantages and disadvantages of the routinely performed 3D CBCT preoperative MMA surgery planning for OSAS patients, regarding 3D volumetric changes of the upper airway and its anatomic subregions and quality of life (QOL) in a subjective manner with the Epworth Sleepiness Scale (ESS) and the OSAS questionnaire and in an objective manner with evaluation of the apnea-hypopnea index (AHI).\n\nDuration\n\nIn light of the continuous improvement of patient care, a database will be maintained from January 2015 onwards to enable registration of large-scale OSAS patient data.\n\nConclusions\n\nDevelopment of a database registering 3D CBCT planning, polysomnographic data and quality of life (QOL) of all consecutive patients eligible for MMA, will provide more information about potential patient, virtual planning and surgical factors influencing accuracy of MMA, and the associated biological benefits of this procedure on the upper airway volume, the AHI and general QOL. Moreover, registration of those results could function as a measurement of quality of care, or could be used for sample size calculation for future large multicenter prospective trials.",[207],"Obstructive Sleep Apnea",[209,210,211,212],"maxillomandibular advancement","obstructive sleep apnea","apnea-hypopnea index","quality of life",{"date":214,"type":32},"2022-02-28",{"date":216,"type":4},"2015-01",{"date":218,"type":21},"2030-06",{"name":38,"class":39},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":227,"targetDuration":157,"studyType":51,"phases":4,"briefSummary":229,"conditions":230,"keywords":234,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":40},"100259802","prospective-registry-of-prosthodontic-rehabilitation-in-oncology-patients-undergoing-jaw-reconstruction-100259802","NCT02661139","Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction","O-BRIDGE","Inclusion Criteria:\n\n* Patients of all ages\n* Patients of all genders\n* Patients with a histologically or clinically confirmed diagnosis of ORN, MRONJ, as classified by Ruggiero et al. (Ruggiero, et al., 2014) or carcinoma located in the oral cavity and jawbone, requiring segmental or total jaw resection\n* Patients eligible for jaw and oral cavity reconstruction combined with immediate\u002Fdelayed implant loading for fixed prosthetic rehabilitation\n* Patients not eligible for conventional removable prosthetic rehabilitation\n\nExclusion Criteria:\n\n* Patients with a clinically confirmed diagnosis of osteonecrosis not related to an oncological diagnosis or treatment\n* Patients with medical contraindications for jaw reconstruction combined with immediate implant loading for fixed prosthetic rehabilitation\n* Patients eligible for conventional removable prosthetic rehabilitation",{"count":228,"type":21},55,"The investigators aim to develop a prospective database in which patient demographics, surgical, dental, prosthetic and QOL parameters collected during consecutive visits within the framework of routine practice, are being registered for each oncological patient eligible for (immediate\u002Fdelayed) fixed prosthodontic rehabilitation at time of oral cavity reconstruction",[231,232,233],"Head and Neck Cancer","Osteonecrosis","Osteoradionecrosis",[235,236,237,212,238],"bisphosphonates","jaw reconstruction","prosthetic rehabilitation","monoclonal antibodies' targeted therapy",{"date":214,"type":32},{"date":241,"type":4},"2013-06",{"date":191,"type":21},{"name":38,"class":39},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":251,"targetDuration":253,"studyType":51,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":40},"100301199","os-anesthesia-followup-of-all-bariatric-procedures-at-one-hospital-100301199","NCT03200964","OS Anesthesia Followup of All Bariatric Procedures at One Hospital","Retrospective Analysis of Anesthesia Delivering for Bariatric Surgery","Inclusion Criteria:\n\n* all bariatric procedures\n\nExclusion Criteria:\n\n* none",{"count":252,"type":21},20000,"1 Month","Database registering demographic patient data, anesthesia and surgery information, post operative recovery and complications if any.",[256],"Anesthesia Recovery","2019-11-17",{"date":259,"type":32},"2019-11-19",{"date":261,"type":32},"2004-01",{"date":263,"type":21},"2030-12-01",{"name":38,"class":39},""]